IRIS
DE LUCA, Giovanna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.487
AS - Asia 3.017
EU - Europa 2.785
SA - Sud America 346
AF - Africa 49
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 2
Totale 10.696
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.411
SG - Singapore 1.177
CN - Cina 847
UA - Ucraina 458
IE - Irlanda 438
GB - Regno Unito 370
TR - Turchia 347
RU - Federazione Russa 319
VN - Vietnam 303
SE - Svezia 289
BR - Brasile 281
DE - Germania 230
IT - Italia 229
FR - Francia 209
FI - Finlandia 131
IN - India 131
CA - Canada 47
HK - Hong Kong 33
JP - Giappone 27
AR - Argentina 24
BD - Bangladesh 24
PL - Polonia 22
MX - Messico 21
IQ - Iraq 19
KR - Corea 18
ZA - Sudafrica 18
CZ - Repubblica Ceca 17
ES - Italia 15
ID - Indonesia 15
EC - Ecuador 12
CL - Cile 11
IR - Iran 10
BE - Belgio 9
EU - Europa 9
LT - Lituania 9
NL - Olanda 9
AE - Emirati Arabi Uniti 8
MA - Marocco 8
CH - Svizzera 7
IL - Israele 7
SA - Arabia Saudita 7
UZ - Uzbekistan 7
AT - Austria 6
CO - Colombia 6
PK - Pakistan 6
RS - Serbia 6
TN - Tunisia 6
KE - Kenya 5
KZ - Kazakistan 5
EG - Egitto 4
ET - Etiopia 4
GR - Grecia 4
JO - Giordania 4
NP - Nepal 4
UY - Uruguay 4
VE - Venezuela 4
AZ - Azerbaigian 3
AM - Armenia 2
AU - Australia 2
BG - Bulgaria 2
BH - Bahrain 2
JM - Giamaica 2
NI - Nicaragua 2
PE - Perù 2
PH - Filippine 2
RO - Romania 2
SY - Repubblica araba siriana 2
AL - Albania 1
BW - Botswana 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
HN - Honduras 1
IM - Isola di Man 1
KG - Kirghizistan 1
KW - Kuwait 1
LB - Libano 1
LV - Lettonia 1
LY - Libia 1
MN - Mongolia 1
MY - Malesia 1
NG - Nigeria 1
PR - Porto Rico 1
PY - Paraguay 1
SR - Suriname 1
TJ - Tagikistan 1
TW - Taiwan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 10.696
Salva come PNG Salva come JPEG
Città #
Singapore 880
Jacksonville 511
Chandler 508
San Jose 443
Dublin 433
Dallas 355
Ashburn 303
Southend 258
Beijing 216
Izmir 192
Princeton 188
Nanjing 151
Wilmington 128
Santa Clara 107
Los Angeles 105
The Dalles 100
Ho Chi Minh City 89
Cambridge 84
Dearborn 84
New York 78
Hanoi 62
Munich 61
Tongling 59
Nanchang 58
Ann Arbor 51
Woodbridge 51
Altamura 45
Buffalo 41
Moscow 41
Council Bluffs 38
Chieti 34
Dong Ket 33
Houston 31
São Paulo 31
Hefei 30
Hong Kong 29
Jiaxing 29
Helsinki 27
Redondo Beach 26
Boardman 25
Shenyang 25
Norwalk 24
Tokyo 23
Frankfurt am Main 22
Tianjin 20
Turku 20
Grevenbroich 19
Kunming 19
Montreal 19
Warsaw 19
London 18
Orem 18
Brooklyn 17
Seoul 17
Washington 17
Hebei 16
Da Nang 15
Stockholm 15
Denver 14
Johannesburg 14
Atlanta 13
Mexico City 13
Toronto 13
Brno 12
Changsha 12
Hangzhou 12
Leawood 12
San Mateo 12
Chennai 11
Chicago 11
Phoenix 11
San Francisco 11
Ardabil 10
Baghdad 10
Nuremberg 10
Poplar 10
Rio de Janeiro 10
Augusta 9
Cedar Knolls 9
Haiphong 9
Jinan 9
Mumbai 9
Torino 9
Amsterdam 8
Biên Hòa 8
Boston 8
Brussels 8
Guangzhou 8
Lanzhou 8
Manchester 8
Pescara 8
Teramo 8
Campobasso 7
Can Tho 7
Monmouth Junction 7
Tashkent 7
Ankara 6
Belgrade 6
Brasília 6
Charlotte 6
Totale 6.757
Salva come PNG Salva come JPEG
Nome #
Integrated Lipidomics and Metabolomics Analysis of Tears in Multiple Sclerosis: An Insight into Diagnostic Potential of Lacrimal Fluid 184
Alzheimer patients treated with an AchE inhibitor show higher IL-4 and lower IL-1β levels and expression in peripheral blood mononuclear cells 175
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis 164
IL 13 in multiple sclerosis 159
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone 154
Increasing age at disability milestones among MS patients in the MSBase Registry 152
The Multiple Sclerosis Knowledge Questionnaire: a self administered instrument for recently diagnosed patients 147
Chemokines are Modulated by Interferon beta 1B (IFNT-Beta IB) in Relapsing-Remitting Multiple Sclerosis (RR-MS) 146
Effetti sinergici della terapia con interferone-beta sulla attivazione, adesione ed apoptosi linfocitaria nella sclerosi multipla esacerbante/remittente 144
Contribution of metabolomics to multiple sclerosis diagnosis, prognosis and treatment 139
Anti-glycolipid and anti-tubulin antibodies in chronic inflammatory demyelinating polyneuropathy 138
Interferon β1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis 138
Effetti sinergici della terapia con interferone-beta sulla attivazione. Adesione ed apoptosi linfocitaria nella sclerosi multipla esacerbante /remittente. (C22) 137
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. 137
Effect of TNF intraneural injection into the rat sciatic nerve 136
Dysimmune demyelinating polyneuropathies: expression of adhesion molecules in sural nerves and changes in cellular immunity (suppressor cell function and cytokine mRNA expression) induced by treatment (progetto presentato a Telethon) 135
Chemokine production by mononuclear cells from relapsing-remitting multiple sclerosis (RR-MS) patients 135
Acetylcholine in multiple sclerosis: possible involvement in the modulation of the immune response and in oligodendrocyte recruitment. 134
Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis 134
Convulsive status epilepticus due to new encephalic demyelinating lesions in multiple sclerosis 133
La funzione soppressoria è ridotta nella polineuropatia demielinizzante cronica infiammatoria (CIDP) 132
A difficult pediatric case: ADEM evolving in multiple sclerosis complicated by progressive multifocal leukoencephalopathy after Natalizumab treatment. 131
Anti-JCV serostatus, index value and clinical features in patients affected by multiple sclerosis. 131
Rantes Levels and mRNA Expression in Relapsing-Remitting Multiple Sclerosis (RR-MS): Effect of interferon Beta 1b (IFNBeta 1b) Treatment 131
A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy 127
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. 125
CD1A and CD1E gene polymorphisms are associated withsusceptibility to multiple sclerosis 124
Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: a prospective study 124
Effect of rhTNF-alpha injection into rat sciatic nerve 122
Breastfeeding is not related to postpartum relapses in multiple sclerosis. 122
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 122
JCV-Ab serostatus in MS patients treated with Natalizumab 121
Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. 121
Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy. 121
MCP-1 expression and secretion in adherent monocyte cultures from multiple sclerosis patients treated with interferon beta-1b 120
Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy. 120
The Chieti experience with Interferon B1b (IFNB1b) during the first 2 years: side effects. 119
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 119
Effects of IL10 on recombinant interferon-beta1b stimulated suppressor cell function in MS and controls subjects 118
Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. 118
rlFN-beta-1B stimulated suppressor cell function in multiple sclerosis: effects of anti-IL-10 monoclonal antibody 115
The Chieti Experience with interferon B1b (IFNB1b) during the first 2 years: Efficacy 115
Rantes and MCP-1 Secretion by Mononuclear Cells of Patients with Nultiple Sclerosis 114
Serum soluble adhesion molecules and proinflammatory cytokines are not increased in chronic inflammatory demyelinating polyneuropathy 114
Nail loss after teriflunomide treatment: a new potential adverse event 114
Interferon beta normalizes suppressor cell function in dysimmune neuropathies 113
Effect of rhTNF-a injection into rat sciatic nerve 113
OXIDATIVE MODIFICATIONS OF CEREBRAL TRANSTHYRETIN ARE ASSOCIATED WITH MULTIPLE SCLEROSIS 112
Interferon beta normalizes suppressor cell function in dysimmune neuropathies. 112
Multiphasic Adem or Multiple Sclerosis? Treatement implications. 111
Low dose oral methotrexate (MTX) in chronic progressive (CP) multiple sclerosis (MS) 110
Interferon beta1b: the Chieti experience 109
Shared T Cell Receptor Usage of Cerebrospinal Fluid Cells in Familial Multiple Sclerosis da: X° National A.I.N.I. Congress Association Italiana Neuroimmunologia - Florence, Italy, November 15/16,1999 109
Neuropsychological testing and quantitative electroencephalography: a search of neurophysiological markers of cognitive decline in multiple sclerosis 106
Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases 105
Prevalence of JC virus antibodies in human serum and seroconversion rate with first-generation and second generation ELISA: the novel assay improves specificity andsensitivity to detect anti-JC virus antibodies 104
Suppressor cell function is decreased in chronic inflammatory demyelinating polyneuropathy 103
Real-life impact of early interferon beta therapy in relapsing multiple sclerosis 103
Proteomic investigations on differential post-translational modification of transthyretin in multiple sclerosis. 103
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 100
A Multicentre italian study on efficacy and safety of Glatiramer Acetate in multiple sclerosis patients with allergic respiratory diseases 100
Livelli sierici e liquorali di IL13 nella Sclerosi Multipla 99
Mononeuropathy following subcutaneous interferon-β injection 99
Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis 98
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register 97
Interferon β 1b: The Chieti experience 96
Patient adherence to and tolerability of self-administered interferon beta-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study 94
Effects of IFN-Beta on rantes and MCP-1 secretion by mononuclear cells frm patients with multiple sclerosis 94
Epilepsy and multiple sclerosis: Clinical, radiological, electrophysiological and neuropsychological aspects 93
Progressive multifocal leukoencephalopathy associated with natalizumab in paediatric multiple sclerosis 93
Treatment discontinuation issues in fingolimod treated patients: the Chieti experience. 93
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 93
IL-13 levels in serum and cerebro-spinal fluid of multiple sclerosis patients 92
Neuropsychological testing and event-related potentials: markers of cognitive impairment in patients with multiple sclerosis 92
Interferon beta normalizes suppressor cell function in dysimmune neuropathies 91
Interferone beta1b: bilancio su un gruppo di 30 pazienti 89
Evaluation of suppressor cell function in chronicn inflammatory demyelinating polyneuropathy (CIDP) 88
Pregnancy and fetal outcomes after paternal exposure to disease modifying drugs for multiple sclerosis 88
mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis 88
Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. 87
Relation between Pro-inflammatory Cytokines and Acetylcholine Levels in Relapsing-Remitting Multiple Sclerosis Patients 86
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society 85
Non-neuronal acetylcholine: a new modulator of immune responses in multiple sclerosis patients. 85
Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients. 82
Modulation of the immune response in multiple sclerosis patients: effect of non-neuronal acetylcholine 81
Pregnancy And Fetal Outcomes After Paternal Exposure To Disease Modifying Drugs For Multiple Sclerosis (P4.157) 81
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 81
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs 79
Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 77
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 76
Progressive multifocal leukoencephalopathy or severe multiple sclerosis relapse following COVID-19 vaccine: a diagnostic challenge 75
Efficacy and safety of glatiramer acetate in multiple sclerosis patients with allergicrespiratory diseases. 75
SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose 74
Gestione degli effetti indesiderati della terapia con interferone beta nella sclerosi multipla 74
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 73
Spinal cord injury in a patient with multiple sclerosis (MS) with secondary hydromyelia 72
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. 66
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 29
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod 27
Epilepsy in MS and its association with cognitive and psychological burden 10
Totale 10.826
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.689
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.689
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021195 0 0 0 0 0 0 0 0 0 68 58 69
2021/2022357 2 4 6 57 11 11 16 34 32 7 54 123
2022/20231.321 104 152 72 158 143 272 81 93 171 17 29 29
2023/2024653 46 30 38 16 37 225 145 30 0 31 5 50
2024/20251.766 117 317 334 26 34 65 42 59 123 94 230 325
2025/20263.440 334 144 500 492 363 204 598 189 391 225 0 0
Totale 10.840